These findings provide effective evidence for the future production of drugs that can either enhance or inhibit PR function; drugs that can enhance PR function would include drugs that can promote its entry into the nucleus to potentially treat RM and that may have clinical application in other progesterone-related conditions, such as endometriosis, while the development of drugs that can inhibit the function of PR may be useful in breast cancer and endometrial cancer. This evidence concerns the gene PGR and endometrial cancer.